Literature DB >> 27104747

STAR syndrome-associated CDK10/Cyclin M regulates actin network architecture and ciliogenesis.

Vincent J Guen1,2, Carly Gamble1, Dahlia E Perez2, Sylvie Bourassa3, Hildegard Zappel4, Jutta Gärtner4, Jacqueline A Lees2, Pierre Colas1.   

Abstract

CDK10/CycM is a protein kinase deficient in STAR (toe Syndactyly, Telecanthus and Anogenital and Renal malformations) syndrome, which results from mutations in the X-linked FAM58A gene encoding Cyclin M. The biological functions of CDK10/CycM and etiology of STAR syndrome are poorly understood. Here, we report that deficiency of CDK10/Cyclin M promotes assembly and elongation of primary cilia. We establish that this reflects a key role for CDK10/Cyclin M in regulation of actin network organization, which is known to govern ciliogenesis. In an unbiased screen, we identified the RhoA-associated kinase PKN2 as a CDK10/CycM phosphorylation substrate. We establish that PKN2 is a bone fide regulator of ciliogenesis, acting in a similar manner to CDK10/CycM. We discovered that CDK10/Cyclin M binds and phosphorylates PKN2 on threonines 121 and 124, within PKN2's core RhoA-binding domain. Furthermore, we demonstrate that deficiencies in CDK10/CycM or PKN2, or expression of a non-phosphorylatable version of PKN2, destabilize both the RhoA protein and the actin network architecture. Importantly, we established that ectopic expression of RhoA is sufficient to override the induction of ciliogenesis resulting from CDK10/CycM knockdown, indicating that RhoA regulation is critical for CDK10/CycM's negative effect on ciliogenesis. Finally, we show that kidney sections from a STAR patient display dilated renal tubules and abnormal, elongated cilia. Altogether, these results reveal CDK10/CycM as a key regulator of actin dynamics and a suppressor of ciliogenesis through phosphorylation of PKN2 and promotion of RhoA signaling. Moreover, they suggest that STAR syndrome is a ciliopathy.

Entities:  

Keywords:  Actin network; CDK10; Cyclin M; PKN2; RhoA; STAR syndrome; ciliogenesis

Mesh:

Substances:

Year:  2016        PMID: 27104747      PMCID: PMC4846108          DOI: 10.1080/15384101.2016.1147632

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  48 in total

1.  Regulation of both PDK1 and the phosphorylation of PKC-zeta and -delta by a C-terminal PRK2 fragment.

Authors:  Conrad P Hodgkinson; Graham J Sale
Journal:  Biochemistry       Date:  2002-01-15       Impact factor: 3.162

2.  The Rho target PRK2 regulates apical junction formation in human bronchial epithelial cells.

Authors:  Sean W Wallace; Ana Magalhaes; Alan Hall
Journal:  Mol Cell Biol       Date:  2010-10-25       Impact factor: 4.272

3.  Regulation of cell polarity and protrusion formation by targeting RhoA for degradation.

Authors:  Hong-Rui Wang; Yue Zhang; Barish Ozdamar; Abiodun A Ogunjimi; Evguenia Alexandrova; Gerald H Thomsen; Jeffrey L Wrana
Journal:  Science       Date:  2003-12-05       Impact factor: 47.728

4.  The PRK2 kinase is a potential effector target of both Rho and Rac GTPases and regulates actin cytoskeletal organization.

Authors:  S Vincent; J Settleman
Journal:  Mol Cell Biol       Date:  1997-04       Impact factor: 4.272

5.  Isolation of a NCK-associated kinase, PRK2, an SH3-binding protein and potential effector of Rho protein signaling.

Authors:  L A Quilliam; Q T Lambert; L A Mickelson-Young; J K Westwick; A B Sparks; B K Kay; N A Jenkins; D J Gilbert; N G Copeland; C J Der
Journal:  J Biol Chem       Date:  1996-11-15       Impact factor: 5.157

6.  Cell shape and contractility regulate ciliogenesis in cell cycle-arrested cells.

Authors:  Amandine Pitaval; Qingzong Tseng; Michel Bornens; Manuel Théry
Journal:  J Cell Biol       Date:  2010-10-18       Impact factor: 10.539

Review 7.  Regulation of F-actin-dependent processes by the Abl family of tyrosine kinases.

Authors:  Pamela J Woodring; Tony Hunter; Jean Y J Wang
Journal:  J Cell Sci       Date:  2003-07-01       Impact factor: 5.285

8.  The cdc-2-related kinase, PISSLRE, is essential for cell growth and acts in G2 phase of the cell cycle.

Authors:  S Li; T K MacLachlan; A De Luca; P P Claudio; G Condorelli; A Giordano
Journal:  Cancer Res       Date:  1995-09-15       Impact factor: 12.701

9.  Actin cytoskeleton reorganization by Syk regulates Fcγ receptor responsiveness by increasing its lateral mobility and clustering.

Authors:  Valentin Jaumouillé; Yoav Farkash; Khuloud Jaqaman; Raibatak Das; Clifford A Lowell; Sergio Grinstein
Journal:  Dev Cell       Date:  2014-06-09       Impact factor: 12.270

10.  Reconstructions of centriole formation and ciliogenesis in mammalian lungs.

Authors:  S P Sorokin
Journal:  J Cell Sci       Date:  1968-06       Impact factor: 5.285

View more
  14 in total

1.  A homozygous deleterious CDK10 mutation in a patient with agenesis of corpus callosum, retinopathy, and deafness.

Authors:  Vincent J Guen; Simon Edvardson; Nitay D Fraenkel; Aviva Fattal-Valevski; Chaim Jalas; Irene Anteby; Avraham Shaag; Talia Dor; David Gillis; Eitan Kerem; Jacqueline A Lees; Pierre Colas; Orly Elpeleg
Journal:  Am J Med Genet A       Date:  2017-11-12       Impact factor: 2.802

2.  The human phosphatase CDC14A modulates primary cilium length by regulating centrosomal actin nucleation.

Authors:  Borhan Uddin; Patrick Partscht; Nan-Peng Chen; Annett Neuner; Manuel Weiß; Robert Hardt; Aliakbar Jafarpour; Bernd Heßling; Thomas Ruppert; Holger Lorenz; Gislene Pereira; Elmar Schiebel
Journal:  EMBO Rep       Date:  2018-11-22       Impact factor: 8.807

3.  CDK10 Mutations in Humans and Mice Cause Severe Growth Retardation, Spine Malformations, and Developmental Delays.

Authors:  Christian Windpassinger; Juliette Piard; Carine Bonnard; Majid Alfadhel; Shuhui Lim; Xavier Bisteau; Stéphane Blouin; Nur'Ain B Ali; Alvin Yu Jin Ng; Hao Lu; Sumanty Tohari; S Zakiah A Talib; Noémi van Hul; Matias J Caldez; Lionel Van Maldergem; Gökhan Yigit; Hülya Kayserili; Sameh A Youssef; Vincenzo Coppola; Alain de Bruin; Lino Tessarollo; Hyungwon Choi; Verena Rupp; Katharina Roetzer; Paul Roschger; Klaus Klaushofer; Janine Altmüller; Sudipto Roy; Byrappa Venkatesh; Rudolf Ganger; Franz Grill; Farid Ben Chehida; Bernd Wollnik; Umut Altunoglu; Ali Al Kaissi; Bruno Reversade; Philipp Kaldis
Journal:  Am J Hum Genet       Date:  2017-09-07       Impact factor: 11.025

Review 4.  The awakening of the CDK10/Cyclin M protein kinase.

Authors:  Vincent J Guen; Carly Gamble; Jacqueline A Lees; Pierre Colas
Journal:  Oncotarget       Date:  2017-07-25

Review 5.  The structure and function of protein kinase C-related kinases (PRKs).

Authors:  Georgios Sophocleous; Darerca Owen; Helen R Mott
Journal:  Biochem Soc Trans       Date:  2021-02-26       Impact factor: 5.407

6.  Balancing the length of the distal tip by septins is key for stability and signalling function of primary cilia.

Authors:  Taishi Kanamaru; Annett Neuner; Bahtiyar Kurtulmus; Gislene Pereira
Journal:  EMBO J       Date:  2021-11-22       Impact factor: 11.598

7.  An EMT-primary cilium-GLIS2 signaling axis regulates mammogenesis and claudin-low breast tumorigenesis.

Authors:  Molly M Wilson; Céline Callens; Matthieu Le Gallo; Svetlana Mironov; Qiong Ding; Amandine Salamagnon; Tony E Chavarria; Roselyne Viel; Abena D Peasah; Arjun Bhutkar; Sophie Martin; Florence Godey; Patrick Tas; Hong Soon Kang; Philippe P Juin; Anton M Jetten; Jane E Visvader; Robert A Weinberg; Massimo Attanasio; Claude Prigent; Jacqueline A Lees; Vincent J Guen
Journal:  Sci Adv       Date:  2021-10-27       Impact factor: 14.136

Review 8.  Cyclin-dependent kinases and rare developmental disorders.

Authors:  Pierre Colas
Journal:  Orphanet J Rare Dis       Date:  2020-08-06       Impact factor: 4.123

Review 9.  Cyclin-Dependent Kinases (CDK) and Their Role in Diseases Development-Review.

Authors:  Paweł Łukasik; Michał Załuski; Izabela Gutowska
Journal:  Int J Mol Sci       Date:  2021-03-13       Impact factor: 5.923

Review 10.  Clinical and genetic heterogeneity of primary ciliopathies (Review).

Authors:  Ina Ofelia Focșa; Magdalena Budișteanu; Mihaela Bălgrădean
Journal:  Int J Mol Med       Date:  2021-07-19       Impact factor: 4.101

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.